Needham & Company Remains Sidelined on Gilead Sciences (GILD) Following 4Q

Needham & Company reiterated a Hold rating on Gilead Sciences (NASDAQ: GILD) following the company's 4Q earnings report.

Analyst Alan Carr commented, "Gilead reported 4Q16 financial results yesterday. Total 4Q16 revenue of $7.32B exceeded our $6.86B and consensus $7.14B estimates, driven by strong Epclusa launch in HCV ($1.05B WW). HCV sales overall, however, continue to fall and mgmt issued 2017 sales guidance below expectations. We remain cautious given revenue trajectory and maintain HOLD."

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $73.13 yesterday.

You May Also Be Interested In

• Stay long AI-capex winners into the peak, Stifel says despite bubble fears
• Hertz cuts guidance, announces notes and stock offerings, shares sink
• Paychex beats fourth quarter EPS estimates, stock slides